These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 36652339)
1. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. Miller J; Hachmann NP; Collier AY; Lasrado N; Mazurek CR; Patio RC; Powers O; Surve N; Theiler J; Korber B; Barouch DH N Engl J Med; 2023 Feb; 388(7):662-664. PubMed ID: 36652339 [No Abstract] [Full Text] [Related]
2. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913 [TBL] [Abstract][Full Text] [Related]
3. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera. Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A Virology; 2024 Jul; 595():110067. PubMed ID: 38653156 [TBL] [Abstract][Full Text] [Related]
4. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Sun C; Kang YF; Liu YT; Kong XW; Xu HQ; Xiong D; Xie C; Liu YH; Peng S; Feng GK; Liu Z; Zeng MS Signal Transduct Target Ther; 2022 Feb; 7(1):42. PubMed ID: 35136040 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349 [TBL] [Abstract][Full Text] [Related]
10. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970 [TBL] [Abstract][Full Text] [Related]
11. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194 [TBL] [Abstract][Full Text] [Related]
13. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843 [TBL] [Abstract][Full Text] [Related]
14. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
15. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
16. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. Miller NL; Clark T; Raman R; Sasisekharan R Cell Rep Med; 2022 Feb; 3(2):100527. PubMed ID: 35233548 [TBL] [Abstract][Full Text] [Related]
17. The great escape? SARS-CoV-2 variants evading neutralizing responses. Prévost J; Finzi A Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702 [TBL] [Abstract][Full Text] [Related]
18. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Liu L; Iketani S; Guo Y; Chan JF; Wang M; Liu L; Luo Y; Chu H; Huang Y; Nair MS; Yu J; Chik KK; Yuen TT; Yoon C; To KK; Chen H; Yin MT; Sobieszczyk ME; Huang Y; Wang HH; Sheng Z; Yuen KY; Ho DD Nature; 2022 Feb; 602(7898):676-681. PubMed ID: 35016198 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620 [TBL] [Abstract][Full Text] [Related]
20. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]